Pacitti David 4/A

What Happened David Pacitti, CEO of Avanos Medical, received two awards of time‑based restricted share units (RSUs) on March 13, 2026: 101,341 RSUs and 239,354 RSUs (total 340,695 RSUs). Both awards were reported as acquisitions at $0.00 (compensation awards), not open‑market purchases or sales. These RSUs are derivative awards that represent the economic equivalent of common shares and will convert to shares if and when they vest.

Key Details

• Transaction date: March 13, 2026; reported on Forms 4/4A filed in March–April 2026. Price: $0.00 (awards).
• Award breakdown and vesting:
  • 101,341 TRSUs: vest 1/3 on 3/13/2027, 1/3 on 3/13/2028, 1/3 on 3/13/2029. (Footnote F1)
  • 239,354 RSUs: vest 30% on 3/13/2027, 30% on 3/13/2028, 40% on 3/13/2029. (Footnote F2)
• Total awarded: 340,695 RSUs (economic equivalent of shares upon vesting).
• Shares owned after the reported transactions: not specified in this filing excerpt.
• Filing note: This is an amendment (Form 4/A) correcting an earlier April 1, 2026 amendment that erroneously added stock options; the original Form 4 filed on March 17, 2026 was correct and reflected the awards. The original March 17 Form 4 was filed within the normal two‑business‑day window following the March 13 transaction.

Context These awards are routine long‑term incentive compensation under Avanos’ 2021 Long‑Term Incentive Plan and are time‑based (not immediate cash or open‑market buying/selling). Because they vest over 2027–2029, they do not represent immediately tradable shares and should be viewed as part of ongoing executive compensation rather than a direct bullish or bearish trading signal.